Movement disorders News and Research RSS Feed - Movement disorders News and Research

Newly developed technique delivers wireless power for optogenetics

Newly developed technique delivers wireless power for optogenetics

A miniature device that combines optogenetics - using light to control the activity of the brain - with a newly developed technique for wirelessly powering implanted devices is the first fully internal method of delivering optogenetics. [More]
Neurocrine completes enrollment in Phase III clinical trial of NBI-98854 in tardive dyskinesia patients

Neurocrine completes enrollment in Phase III clinical trial of NBI-98854 in tardive dyskinesia patients

Neurocrine Biosciences, Inc. announced today that it has recently completed subject randomization of the Phase III clinical trial (Kinect 3 Study) of its proprietary Vesicular Mono-Amine Transporter 2 (VMAT2) compound NBI-98854 in tardive dyskinesia patients. [More]
Early cognitive changes linked to white matter damage in Parkinson’s

Early cognitive changes linked to white matter damage in Parkinson’s

Subtle changes in white matter integrity are detectable in patients with Parkinson’s disease and are associated with early impairments in cognition, say researchers. [More]
Study sheds light on certain antagonist drugs that block physiological responses

Study sheds light on certain antagonist drugs that block physiological responses

Members of the Consolidated Research Group of Molecular Neurobiology of the Department of Biochemistry and Molecular Biology of the University of Barcelona (UB), affiliated with the Centre for Networked Biomedical Research on Neurodegenerative Diseases (CIBERNED), have published a study in the journal Proceedings of the National Academy of Sciences (PNAS) about the formation of G protein-coupled receptors (GPCRs) which allows understanding the unexpected behaviour of some antagonists that block physiological responses. [More]
NYU Langone receives $25 million to establish Fresco Institute for PD and movement disorders

NYU Langone receives $25 million to establish Fresco Institute for PD and movement disorders

NYU Langone Medical Center today announced that the Paolo and Marlene Fresco Foundation (Fresco Foundation) has generously given $25 million to establish the international Marlene and Paolo Fresco Institute for Parkinson's & Movement Disorders. [More]
Clinical studies confirm safety, efficacy of opicapone in Parkinson’s disease patients

Clinical studies confirm safety, efficacy of opicapone in Parkinson’s disease patients

BIAL is presenting 11 research posters at the 19th International Congress of Parkinson's Disease and Movement Disorders (June 14–15, San Diego, CA). These evaluate the safety and efficacy of opicapone (BIA 9-1067), a novel once-daily catechol-O-methyltransferase (COMT) inhibitor for use as adjunctive therapy in levodopa-treated Parkinson’s disease patients with end of dose motor fluctuations. [More]
NTCELL Phase I/IIa clinical study meets primary endpoint in patients with Parkinson’s disease

NTCELL Phase I/IIa clinical study meets primary endpoint in patients with Parkinson’s disease

Living Cell Technologies Limited today announced results from a Phase I/IIa clinical study of NTCELL, an experimental regenerative cell therapy being studied as a disease-modifying agent in Parkinson’s disease. The study, conducted in four patients in New Zealand, met its primary endpoint of safety, showing NTCELL implantation was well tolerated, with no adverse events considered to be related to NTCELL. [More]
INS announces winners of inaugural best abstract competition at 12th World Congress

INS announces winners of inaugural best abstract competition at 12th World Congress

The International Neuromodulation Society (INS) announced winners today of its inaugural best abstract competition at the 12th World Congress in Montreal. [More]
UT Southwestern researchers reveal how the body controls glucose transport

UT Southwestern researchers reveal how the body controls glucose transport

UT Southwestern Medical Center scientists have gleaned a key cellular mechanism of how the body adjusts glucose levels, an important process that when abnormal can promote diabetes, cancer, and rare genetic diseases. [More]
New York Eye and Ear Infirmary of Mount Sinai observes June 1st as World Orthoptics Day

New York Eye and Ear Infirmary of Mount Sinai observes June 1st as World Orthoptics Day

New York Eye and Ear Infirmary of Mount Sinai joins with the International Orthoptic Association to observe June 1st as World Orthoptics Day. [More]
New research points to potential therapeutic target for treating multiple sclerosis

New research points to potential therapeutic target for treating multiple sclerosis

New research into the causes of the excessive inflammation that drives multiple sclerosis has identified a faulty "brake" within immune cells, a brake that should be controlling the inflammation. This points to a potential target for developing new therapies to treat multiple sclerosis and could have important implications for other autoimmune diseases, such as the colon disease colitis and the chronic skin condition atopic dermatitis. [More]
β-amyloid deposition highly variable in synucleinopathy

β-amyloid deposition highly variable in synucleinopathy

A meta-analysis suggests large variability in the prevalence of β-amyloid deposition in patients with synucleinopathies. [More]
Neurocrine reports net loss of $1.2 million for first quarter 2015

Neurocrine reports net loss of $1.2 million for first quarter 2015

Neurocrine Biosciences, Inc. today announced its financial results for the quarter ended March 31, 2015. For the first quarter of 2015, the Company reported a net loss of $1.2 million, or $0.01 loss per share, compared to a net loss of $11.8 million, or $0.17 loss per share, for the same period in 2014. [More]
Parents share arduous, circuitous journey to get referrals for childhood epilepsy surgery

Parents share arduous, circuitous journey to get referrals for childhood epilepsy surgery

Having a child diagnosed with epilepsy can be a frightening and confusing time. Now, parents share their arduous and "circuitous" journey to get referrals for pediatric epilepsy surgery once their child's disease stops responding to anti-seizure medications. The UCLA study sheds light on the difficulties parents face obtaining specialty and sub-specialty care for their children during an already stressful time. [More]
Boston Scientific, Brainlab form strategic collaboration

Boston Scientific, Brainlab form strategic collaboration

Boston Scientific Corporation announces a collaboration with Brainlab AG, a leading software-driven medical technology company that helps improve patient treatment planning and surgical navigation. [More]
Impulse control disorders do not promote cognitive decline in PD

Impulse control disorders do not promote cognitive decline in PD

Impulse control disorders in patients with Parkinson’s disease are not associated with more marked impairment of cognitive function, researchers report. [More]
Early neuropsychiatric symptoms prevalent in PD

Early neuropsychiatric symptoms prevalent in PD

Neuropsychiatric symptoms, but not cognitive impairment, are common in early untreated patients with Parkinson’s disease, suggest findings from the multicentre Parkinson’s Progression Markers Initiative. [More]
New blood test may more accurately identify biomarkers for Parkinson's disease

New blood test may more accurately identify biomarkers for Parkinson's disease

A new blood test may more accurately identify blood signatures, or biomarkers, for Parkinson's disease (PD), according to a new study published in the journal Movement Disorders. [More]
Neurocrine Biosciences, Mitsubishi Tanabe to develop and commercialize NBI-98854 in select Asian markets

Neurocrine Biosciences, Mitsubishi Tanabe to develop and commercialize NBI-98854 in select Asian markets

Neurocrine Biosciences, Inc. today announced that it has entered into an exclusive collaboration and licensing agreement for the development and commercialization of its VMAT2 inhibitor, NBI-98854, in Japan and other select Asian markets with Mitsubishi Tanabe Pharma Corporation. [More]
Northwestern Medicine opens multidisciplinary treatment center for patients battling Huntington's disease

Northwestern Medicine opens multidisciplinary treatment center for patients battling Huntington's disease

Northwestern Medicine recently launched a multidisciplinary center dedicated to the comprehensive treatment of patients battling Huntington's disease. The new center will focus on both patient care and research of the inherited disease that causes the progressive breakdown of nerve cells in the brain. [More]
Advertisement
Advertisement